

Georgios K Dimitriadis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5584325/publications.pdf>

Version: 2024-02-01

74
papers

1,040
citations

567281

15
h-index

454955

30
g-index

75
all docs

75
docs citations

75
times ranked

1475
citing authors

#	ARTICLE	IF	CITATIONS
1	Duodenal-jejunal Bypass Liner for the management of Type 2 Diabetes Mellitus and Obesity. <i>Annals of Surgery</i> , 2022, 275, 440-447.	4.2	16
2	Effects of glucagon-like peptide-1 receptor agonists on histopathological and secondary biomarkers of non-alcoholic steatohepatitis: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 337-342.	4.4	4
3	Endocrine abnormality in paraneoplastic syndrome. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2022, 36, 101621.	4.7	6
4	Multiple electrolyte disturbances as the presenting feature of multiple endocrine neoplasia type 1 (MEN-1). <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2022, 2022, .	0.5	0
5	A cytokine panel and procalcitonin in COVID-19, a comparison between intensive care and non-intensive care patients. <i>PLoS ONE</i> , 2022, 17, e0266652.	2.5	11
6	Does Bypass of the Proximal Small Intestine Impact Food Intake, Preference, and Taste Function in Humans? An Experimental Medicine Study Using the Duodenal-jejunal Bypass Liner. <i>Nutrients</i> , 2022, 14, 2141.	4.1	4
7	Comparison of mechanistic pathways of bariatric surgery in patients with diabetes mellitus: A Bayesian network meta-analysis. <i>Obesity</i> , 2022, 30, 1380-1390.	3.0	7
8	Glucocorticoid-Induced Hypocalcemia in a Patient with Established Hypoparathyroidism. <i>American Journal of Medicine</i> , 2021, 134, e321-e322.	1.5	3
9	Simple tool to prioritize access to bariatric surgery for people living with obesity during the COVID-19 pandemic. <i>British Journal of Surgery</i> , 2021, 108, e179-e180.	0.3	4
10	Calcitonin-secreting neuroendocrine neoplasms of the lung: a systematic review and narrative synthesis. <i>Endocrine Connections</i> , 2021, 10, 447-461.	1.9	5
11	Biochemical abnormalities in COVID-19: a comparison of white versus ethnic minority populations in the UK. <i>Journal of Clinical Pathology</i> , 2021, , jclinpath-2021-207446.	2.0	2
12	Weight loss with bariatric surgery or behaviour modification and the impact on female obesity-related urine incontinence: A comprehensive systematic review and meta-analysis. <i>Clinical Obesity</i> , 2021, 11, e12450.	2.0	10
13	Identification of an optimal prolactin threshold to determine prolactinoma size using receiver operating characteristic analysis. <i>Scientific Reports</i> , 2021, 11, 9801.	3.3	8
14	Mechanisms of action of duodenal mucosal resurfacing in insulin resistant women with polycystic ovary syndrome. <i>Metabolism: Clinical and Experimental</i> , 2021, 125, 154908.	3.4	7
15	Metabolic syndrome is associated with prostate enlargement: a systematic review, meta-analysis, and meta-regression on patients with lower urinary tract symptom factors. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2021, 12, 204201882110662.	3.2	2
16	Plerixafor-aided Mobilization of Peripheral Blood Hematopoietic Stem Cells to Support Subsequent High-dose Chemotherapy After a Prior Autologous Transplant. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e50-e57.	0.4	1
17	Orexin-A Exerts Equivocal Role in Atherosclerosis Process Depending on the Duration of Exposure: In Vitro Study. <i>Nutrients</i> , 2020, 12, 53.	4.1	2
18	Ectopic hyperprolactinaemia due to a malignant uterine tumor resembling ovarian sex cord tumors (UTROCST). <i>Pituitary</i> , 2020, 23, 641-647.	2.9	10

#	ARTICLE	IF	CITATIONS
19	The relationship between obstructive sleep apnoea and quality of life in women with polycystic ovary syndrome: a cross-sectional study. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2020, 11, 204201882090668.	3.2	9
20	Paraneoplastic hypoglycaemia secondary to IGF-2 secretion from a metastatic gastrointestinal stromal tumour. <i>Endocrine and Metabolic Science</i> , 2020, 1, 100047.	1.6	1
21	Male Obesity Associated Gonadal Dysfunction and the Role of Bariatric Surgery. <i>Frontiers in Endocrinology</i> , 2020, 11, 408.	3.5	19
22	Laparoscopic Adjustable Gastric Banding—Should a Second Chance Be Given?. <i>Obesity Surgery</i> , 2020, 30, 2913-2919.	2.1	7
23	Effects of visfatin on brown adipose tissue energy regulation using T37i cells. <i>Cytokine</i> , 2019, 113, 248-255.	3.2	9
24	Empagliflozin improves primary haemodynamic parameters and attenuates the development of atherosclerosis in high fat diet fed APOE knockout mice. <i>Molecular and Cellular Endocrinology</i> , 2019, 494, 110487.	3.2	35
25	Endocrine paraneoplastic syndromes in patients with neuroendocrine neoplasms. <i>Endocrine</i> , 2019, 64, 384-392.	2.3	12
26	Tumour Detection in Syndromic NET: Carcinoid Syndrome. , 2018, , 161-169.		1
27	Metabolic phenotype of male obesity-related secondary hypogonadism pre-replacement and post-replacement therapy with intra-muscular testosterone undecanoate therapy. <i>Endocrine</i> , 2018, 60, 175-184.	2.3	16
28	Identification of an optimal threshold for detecting human brown adipose tissue using receiver operating characteristic analysis of IDEAL MRI fat fraction maps. <i>Magnetic Resonance Imaging</i> , 2018, 51, 61-68.	1.8	21
29	Glucagon Like Peptide 2 (GLP-2). , 2018, , 561-564.		0
30	Functional cardiac orexin receptors: role of orexin-B/orexin 2 receptor in myocardial protection. <i>Clinical Science</i> , 2018, 132, 2547-2564.	4.3	15
31	Supplementation of Vitamin D Deficiency in Patients with Neuroendocrine Tumors Using Over-the-Counter Vitamin D3 Preparations. <i>Nutrition and Cancer</i> , 2018, 70, 748-754.	2.0	16
32	The value of prolactin in predicting prolactinoma in hyperprolactinaemic polycystic ovarian syndrome. <i>European Journal of Clinical Investigation</i> , 2018, 48, e12961.	3.4	15
33	Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice. <i>Cardiovascular Diabetology</i> , 2018, 17, 106.	6.8	118
34	Chemerin induces endothelial cell inflammation: activation of nuclear factor-kappa beta and monocyte-endothelial adhesion. <i>Oncotarget</i> , 2018, 9, 16678-16690.	1.8	49
35	Microvascular complications after metabolic surgery. <i>Lancet Diabetes and Endocrinology</i> , the, 2017, 5, 240-241.	11.4	1
36	Hypertestosteronemia and Infertility from a Mediastinal Extragonadal Germ Cell Tumor. <i>American Journal of Medicine</i> , 2017, 130, e261-e263.	1.5	3

#	ARTICLE	IF	CITATIONS
37	Molecular targeted therapies in adrenal, pituitary and parathyroid malignancies. <i>Endocrine-Related Cancer</i> , 2017, 24, R239-R259.	3.1	16
38	Brown fat depots in adult humans remain static in their locations on PET/CT despite changes in seasonality. <i>Physiological Reports</i> , 2017, 5, e13284.	1.7	6
39	Paraneoplastic endocrine syndromes. <i>Endocrine-Related Cancer</i> , 2017, 24, R173-R190.	3.1	54
40	Potential Hormone Mechanisms of Bariatric Surgery. <i>Current Obesity Reports</i> , 2017, 6, 253-265.	8.4	109
41	Plerixafor mobilization of peripheral blood hematopoietic progenitors to support further high-dose chemotherapy cycles in a patient with germ-cell tumor relapsing after previous tandem high-dose chemotherapy and hematopoietic cell transplantation. <i>Anti-Cancer Drugs</i> , 2017, 28, 237-241.	1.4	5
42	PCOS remains a diagnosis of exclusion: a concise review of key endocrinopathies to exclude. <i>Clinical Endocrinology</i> , 2017, 86, 1-6.	2.4	31
43	Glyoxalase 1 copy number variation in patients with well differentiated gastro-entero-pancreatic neuroendocrine tumours (GEP-NET). <i>Oncotarget</i> , 2017, 8, 76961-76973.	1.8	5
44	Medical management of secretory syndromes related to gastroenteropancreatic neuroendocrine tumours. <i>Endocrine-Related Cancer</i> , 2016, 23, R423-R436.	3.1	59
45	Obesity-related metabolic and reproductive dysfunction: variations between the sexes. <i>Expert Review of Endocrinology and Metabolism</i> , 2016, 11, 387-393.	2.4	2
46	Screening for malnutrition in patients with gastro-entero-pancreatic neuroendocrine tumours: a cross-sectional study. <i>BMJ Open</i> , 2016, 6, e010765.	1.9	34
47	Polycystic ovary syndrome: insight into pathogenesis and a common association with insulin resistance. <i>Clinical Medicine</i> , 2016, 16, 262-266.	1.9	71
48	Short-Chain Fatty Acid Acetate Stimulates Adipogenesis and Mitochondrial Biogenesis via GPR43 in Brown Adipocytes. <i>Endocrinology</i> , 2016, 157, 1881-1894.	2.8	91
49	Polycystic Ovary Syndrome as a Proinflammatory State: The Role of Adipokines. <i>Current Pharmaceutical Design</i> , 2016, 22, 5535-5546.	1.9	31
50	Polycystic ovary syndrome: insight into pathogenesis and a common association with insulin resistance. <i>Clinical Medicine</i> , 2015, 15, s72-s76.	1.9	62
51	Severe paraneoplastic hypoglycemia secondary to a gastrointestinal stromal tumour masquerading as a stroke. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2015, 2015, 150062.	0.5	4
52	Plerixafor added to G-CSF-supported paclitaxel-ifosfamide-cisplatin salvage chemotherapy enhances mobilization of adequate numbers of hematopoietic stem cells for subsequent autografting in hard-to-mobilize patients with relapsed/refractory germ-cell tumors. <i>Anti-Cancer Drugs</i> , 2014, 25, 841-847.	1.4	10
53	Refractory Graves' disease following total thyroidectomy caused by concurrent ectopic thyroid tissue in the anterior mediastinum. <i>Endocrine Abstracts</i> , 0, , .	0.0	0
54	Liraglutide 3.0 mg within a NHS Tier-3/4 weight management service results in similar weight loss compared to regulatory trials - The LIPOSAX first UK real-world evidence study. <i>Obesity Abstracts</i> , 0, , .	0.0	0

#	ARTICLE	IF	CITATIONS
55	Investigation of the mechanism of action of duodenal mucosal resurfacing in insulin resistant women with polycystic ovarian syndrome. the DOMINO multicentre randomised controlled trial. Endocrine Abstracts, 0, , .	0.0	1
56	Somatostatin responsive ACTH and precursor excess in a midgut mesentery NET. Endocrine Abstracts, 0, , .	0.0	0
57	Hypertestosteronemia and primary infertility due to an extragonadal germ cell tumor of the anterior mediastinum. Endocrine Abstracts, 0, , .	0.0	0
58	Nuclear factor-kappa beta activation and monocyte-endothelial adhesion lead to chemerin induced endothelial cell inflammation. Endocrine Abstracts, 0, , .	0.0	0
59	UHCW audit on SGLT2 inhibitor (SGLT2-i) use. Endocrine Abstracts, 0, , .	0.0	0
60	Metabolic phenotype of Male Obesity-associated Secondary Hypogonadism pre- and post-replacement therapy with intra-muscular Testosterone undecanoate therapy. Endocrine Abstracts, 0, , .	0.0	0
61	Hypertestosteronemia and primary infertility from a mediastinal extragonadal germ cell tumor. Endocrine Abstracts, 0, , .	0.0	0
62	Supplementation of vitamin D deficiency/insufficiency in patients with GEP-NET using over the counter vitamin D3 preparations. Endocrine Abstracts, 0, , .	0.0	0
63	Canagliflozin attenuates the progression of atherosclerosis via reducing hyperlipidaemia and inflammation process in ApoE KO Mice. Endocrine Abstracts, 0, , .	0.0	0
64	Effects of visfatin on brown adipose tissue energy regulation. Endocrine Abstracts, 0, , .	0.0	0
65	Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice. Endocrine Abstracts, 0, , .	0.0	0
66	Prolactin as a surrogate marker of prolactinoma diagnosis in PCOS. Endocrine Abstracts, 0, , .	0.0	0
67	Long-term administration of Empagliflozin may promote hepatic and renal lipid accumulation, and inflammation in the APOE knockout model. Endocrine Abstracts, 0, , .	0.0	0
68	In vitro study of Orexin alpha effects on factors involved in atherosclerosis: a dual role?. Endocrine Abstracts, 0, , .	0.0	0
69	Empagliflozin inhibits apoptosis of pancreatic beta-cells through amelioration of ER-stress.. Endocrine Abstracts, 0, , .	0.0	0
70	Empagliflozin attenuates the progression of atherosclerosis in APO-E knockout mice. Endocrine Abstracts, 0, , .	0.0	0
71	Weight loss and change in obesity related comorbidities in patients undergoing laparoscopic adjustable gastric banding at UHCW between 2009 and 2012. Endocrine Abstracts, 0, , .	0.0	0
72	Liraglutide downregulates the expression of miRNA-424 in patients with obesity. Endocrine Abstracts, 0, , .	0.0	0

#	ARTICLE	IF	CITATIONS
73	Liraglutide downregulates the expression of miRNA-424 in patients with obesity. Obesity Abstracts, 0, , .	0.0	0
74	3 mg Liraglutide ameliorates inflammation and improves hypothalamic regulation of energy homeostasis by modulation of Sphingosine-1-Phosphate signalling in super-responders. Endocrine Abstracts, 0, , .	0.0	0